Castle Biosciences

company

About

Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.

  • 251 - 500

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$5.05M
Industries
Biotechnology,Health Care,Health Diagnostics
Founded date
Jan 1, 2008
Number Of Employee
251 - 500
Operating Status
Active

Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. The company also focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions.

The DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed and the DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer, including the risk of sentinel lymph node positivity.

Castle Biosciences was founded in 2008 and is headquartered in Friendswood, Texas, United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$16.85M
Castle Biosciences has raised a total of $16.85M in funding over 2 rounds. Their latest funding was raised on Jun 11, 2018 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 11, 2018 Series Unknown $5.05M 1 Detail
Aug 13, 2014 Series Unknown $11.80M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Castle Biosciences is funded by 2 investors. MGC Venture Partners and Longfellow Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
MGC Venture Partners Series Unknown
Longfellow Venture Partners Series Unknown

Acquisition

Castle Biosciences has acquired 1 organizations. Their most recent acquisition was Cernostics on Oct 19, 2021. They acquired Cernostics for $30M.

Date Company Name
Industry Acquisition Type Price
Oct 19, 2021 Cernostics
Biotechnology acquisition $ 30M Detail